CR20200510A - Protreínas de fusión del factor de diferenciación de crecimiento 15 - Google Patents

Protreínas de fusión del factor de diferenciación de crecimiento 15

Info

Publication number
CR20200510A
CR20200510A CR20200510A CR20200510A CR20200510A CR 20200510 A CR20200510 A CR 20200510A CR 20200510 A CR20200510 A CR 20200510A CR 20200510 A CR20200510 A CR 20200510A CR 20200510 A CR20200510 A CR 20200510A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
differentiation factor
growth differentiation
gdf15
region
Prior art date
Application number
CR20200510A
Other languages
English (en)
Inventor
ELLISON Murielle Marie VENIANT
Yumei Xiong
Kenneth William Walker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20200510A publication Critical patent/CR20200510A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>En el presente documento se proporcionan molécula de Fcs de GDF15. En algunas realizaciones, la molécula de Fc de GDF15 es una fusión GDF15-Fc, en la que se fusiona una región de GDF15 a una región de Fc. En algunas realizaciones, la región de GDF15 está fusionada a la región de Fc mediante un enlazador. También, en el presente documento se proporcionan métodos para crear y usar molécula de Fcs de GDF15.</p>
CR20200510A 2018-04-09 2019-04-08 Protreínas de fusión del factor de diferenciación de crecimiento 15 CR20200510A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655108P 2018-04-09 2018-04-09
PCT/US2019/026369 WO2019199685A1 (en) 2018-04-09 2019-04-08 Growth differentiation factor 15 fusion proteins

Publications (1)

Publication Number Publication Date
CR20200510A true CR20200510A (es) 2020-11-26

Family

ID=66251865

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200510A CR20200510A (es) 2018-04-09 2019-04-08 Protreínas de fusión del factor de diferenciación de crecimiento 15

Country Status (23)

Country Link
US (3) US20230143988A1 (es)
EP (1) EP3773656A1 (es)
JP (2) JP7058670B2 (es)
KR (1) KR20200140878A (es)
CN (1) CN111954537A (es)
AR (1) AR114476A1 (es)
AU (1) AU2019253462A1 (es)
BR (1) BR112020020823A2 (es)
CA (1) CA3096097A1 (es)
CL (1) CL2020002585A1 (es)
CO (1) CO2020012563A2 (es)
CR (1) CR20200510A (es)
EA (1) EA202092419A1 (es)
IL (1) IL277842A (es)
JO (1) JOP20200258A1 (es)
MA (1) MA52205A (es)
MX (1) MX2020010659A (es)
PE (1) PE20201350A1 (es)
PH (1) PH12020551655A1 (es)
SG (1) SG11202009884YA (es)
TW (1) TW202003586A (es)
UY (1) UY38177A (es)
WO (1) WO2019199685A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017152105A1 (en) * 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
EP3934679A1 (en) * 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
MX2021012964A (es) * 2019-04-23 2021-12-10 Lg Chemical Ltd Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15.
TW202140525A (zh) * 2020-01-08 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 Ｆｇｆ２１突變體蛋白及其融合蛋白
WO2022092915A1 (ko) * 2020-10-30 2022-05-05 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물
WO2023025120A1 (en) * 2021-08-24 2023-03-02 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
CA2356401A1 (en) 1999-01-07 2000-07-13 Lexigen Pharmaceuticals, Corp. Expression and export of anti-obesity proteins as fc fusion proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
WO2002072608A2 (en) 2001-03-09 2002-09-19 University Of Chicago POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7737260B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CN1974601A (zh) 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CN101854947A (zh) 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
JP2011523051A (ja) 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
CA2732449A1 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
WO2010048670A1 (en) 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
AU2010326024A1 (en) 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
EP2593431B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
ES2627337T3 (es) 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9714276B2 (en) * 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
AR094271A1 (es) 2012-12-21 2015-07-22 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6272907B2 (ja) * 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
NZ754961A (en) * 2013-07-31 2022-04-29 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
ES2818109T3 (es) 2014-06-23 2021-04-09 Novartis Ag Modificaciones de proteínas específicas para un sitio
AU2015279525A1 (en) 2014-06-24 2016-12-15 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
WO2017152105A1 (en) 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
BR112018072034A2 (pt) 2016-05-24 2019-02-12 Novo Nordisk A/S compostos mic-1 e usos dos mesmos
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
JOP20200258A1 (ar) 2020-10-11
PH12020551655A1 (en) 2021-07-26
MX2020010659A (es) 2020-10-28
UY38177A (es) 2019-07-31
CN111954537A (zh) 2020-11-17
WO2019199685A1 (en) 2019-10-17
SG11202009884YA (en) 2020-11-27
US20230143988A1 (en) 2023-05-11
US20220017584A1 (en) 2022-01-20
PE20201350A1 (es) 2020-11-30
AR114476A1 (es) 2020-09-09
EA202092419A1 (ru) 2021-02-05
JP2022095856A (ja) 2022-06-28
EP3773656A1 (en) 2021-02-17
JP2020533271A (ja) 2020-11-19
TW202003586A (zh) 2020-01-16
US20210147500A1 (en) 2021-05-20
CO2020012563A2 (es) 2020-10-30
MA52205A (fr) 2021-02-17
IL277842A (en) 2020-11-30
KR20200140878A (ko) 2020-12-16
CA3096097A1 (en) 2019-10-17
CL2020002585A1 (es) 2020-12-04
AU2019253462A1 (en) 2020-11-26
US11161889B2 (en) 2021-11-02
JP7058670B2 (ja) 2022-04-22
BR112020020823A2 (pt) 2021-01-19

Similar Documents

Publication Publication Date Title
CR20200510A (es) Protreínas de fusión del factor de diferenciación de crecimiento 15
MX2021010737A (es) Terapia de combinacion por factor de diferenciacion del crecimiento 15.
EA202090216A2 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
EP3539982A3 (en) Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2020072821A3 (en) Il-12 heterodimeric fc-fusion proteins
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
WO2021041715A3 (en) Compositions including igg fc mutations and uses thereof
AU2003215188A1 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
SG11201901495YA (en) Method for producing antibody fusion protein
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
EA202191105A1 (ru) Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
MY190624A (en) Anti-vegf protein compositions and methods for producing the same
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
AU2018226215B2 (en) Immunoconjugates with optimized linkers and orientation
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2023001595A (es) Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas.
CL2021002757A1 (es) Polipéptido de fusión que comprende región fc de inmunoglobulina y gdf15.
DK2059525T3 (da) Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse
EA201792274A1 (ru) Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
AU2018276376A1 (en) Cell culture methods